{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Limit to 41 evaluable patients who received dose 1.8 mg/kg","groups":[{"description":"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.\n\nBrentuximab Vedotin: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)"}],"populationDescription":"These samples were banked but not analyzed, due to a change in research priorities.","reportingStatus":"POSTED","timeFrame":"From the end of first dose to the end of last dose (Up to 13 Months)","title":"Correlation Between Micro Ribonucleic Acid (miRNA) and Disease Response to Protocol Treatment","type":"SECONDARY"}